

Description: Scholarship Competition – Entrepreneurship in Oncology (CEO)

CONTEXT

[IRICoR](#) and [Oncopole](#) join forces to launch the third edition of the Scholarship Competition – Entrepreneurship in Oncology (CEO), offering the next generation of scientists an opportunity to develop their entrepreneurial skills, along with their academic skills. Thus, both organizations will offer training scholarships, as part of the [Life Sciences Entrepreneurship Development Program](#), created through a partnership between Montréal InVivo, Université de Montréal's Faculty of Pharmacy and Concordia University's John Molson Executive Centre, in collaboration with TransMedtech and IRICoR.

WHY TAKE PART IN THE PROGRAM?

This practical and immersive training, the result of a joint effort between key players in life sciences from both industry and academia, will allow you to familiarize yourself with the development stages of an innovative company, from the lab to the market, through current management models that apply to both the research and the commercialization of innovation stages.

BRIEF OVERVIEW

- The program includes 10 intensive 2-day modules (Friday and Saturday, once a month, classes taught in Montreal) from February 2020 to January 2021, in order to allow you to gradually apply the knowledge acquired to the challenges you face on a daily basis.
- Furthermore, by taking part in this third cohort limited to about thirty candidates, you will be contributing to the progression of a tangible project with other participants from various backgrounds, thus allowing you to forge links with different players in the life science sector.

For more information, go to:

<https://www.concordia.ca/jmsb/executive-education/expertise/health-management/life-sciences-entrepreneurship-development.html>

OBJECTIVE OF THE CEO COMPETITION

IRICoR and the Oncopole want to ensure the training of the next generation of scientists through better tools for project management and entrepreneurial skills. Both organizations aim to identify the most promising candidates in the ecosystem and make it easier for them to get a training that meets their needs.

ELIGIBILITY OF APPLICANTS

PhD candidates, Postdoctoral Fellows and Young Investigators (max 10 years in position) affiliated with a Canadian teaching or research institution, at the time of application submission, are eligible.

SCHOLARSHIP AMOUNT

The scholarship amount awarded to each recipient will cover the full program registration fees, namely \$5,890 + taxes. Furthermore, applicants residing outside the Montreal metropolitan area could be reimbursed for part of their travel and accommodation costs for having participated in the program.

TIMELINE AND EVALUATION


Applicants must fill out the form (attached or below) and send it to ferima.sanogo@umontreal.ca, by **November 08th 2019**, at 5:00pm. The applicants can also contact Audrey for any question on the competition.

Applicants will be informed of the results by December 13th 2019. Applications will be assessed according to the following scorecard:

Scoring	Sections	Criteria
-	1. Applicant information	-
25%	2. Research experience: 100 words – Relevance of your research project or your career to oncology 100 words – Academic distinction 100 words – Scientific communication	Activities and achievements to date
40%	3. Motivation: 500 words – Motivation & expectations with respect to the program	Potential shown Alignment of program/career goals
35%	4. Entrepreneurial experience 500 words – Proposed project Or 500 words – Relevance of previous entrepreneurial experience (3 max.)	Demonstration of the applicant’s sense of entrepreneurship Perspective and potential of the proposed project. General characteristics and skills Entrepreneurial experience and skills demonstrated

FILLING OUT AND SENDING THE FORM

- Make sure to download and save the document onto your computer in order to fill it out.
- Please title the document as follows: *Last name_application_form_CEO*, and then send it to ferima.sanogo@umontreal.ca, by **November 08th 2019**, 5:00pm.
- The document must be sent in .pdf format.



APPLICANT'S COMMITMENT

By submitting his/her application, the applicant must agree:

- To attend all sessions of the Life Sciences Entrepreneurship Development Program.
- Following completion of the program, to provide the Oncopole and IRICoR with his/her assessment of said program and of the competition; this assessment to be done when and how the Oncopole and IRICoR deem fit (e.g. meeting, report, form, etc.).
- To authorize the Oncopole and IRICoR to keep and to use all of the information contained in its file provided that all personal information will remain confidential.

For more information about the Life Sciences Entrepreneurship Development Program, please contact:


Valérie Lancelot-Mingot

Programs Manager

John Molson School of Business

514 848-3960

valerie.lancelot-mingot@concordia.ca



About the Oncopole

The Oncopole is Quebec's hub for research, development and investment to accelerate the fight against cancer. Created in February of 2017, it is the product of a unique co-creation process led by the Fonds de recherche du Québec – Santé (FRQS) and made possible by an initial \$15M investment from Merck Canada. The Oncopole's mission is to act as a catalyst leveraging actions made by the key players in Quebec's oncology and innovation research ecosystem. As a result, it aims to position the province as a leader in the field. Its priorities of action, namely research, entrepreneurship, commercialization and integration of innovation, as well as clinical relevance, are orchestrated in order to foster the mobilization of stakeholders, the discovery of innovative approaches to fight cancer and, ultimately, a positive impact for the benefit of patients. For more information about Oncopole, go to: oncopole.ca

About the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)

As a project maturation cluster in the field of drug discovery, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal. IRICoR's mandate is to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since 2008, IRICoR has successfully combined industry-standard business expertise and cutting-edge research. IRICoR invests in and supports particularly innovative selected projects, ensuring an effective transition of fundamental research into innovative therapies, through either co-development partnerships with the biopharmaceutical industry or the creation of spin-off companies. IRICoR provides selected academic and industry projects with access to its drug discovery network of experts and infrastructure, including one of the largest academia-based medicinal chemistry groups in Canada. IRICoR's major funding sources for the 2018-2023 period include the Canadian government's Centres of Excellence for Commercialization and Research (CECR) program, Québec government's programs through the *Ministère de l'Économie, de la Science et de l'Innovation* (MESI), and collaborative partnerships with the biopharmaceutical industry. For more information about IRICoR, go to: iricor.ca